Search

Displaying results 4611 - 4620 of 9322 in total
  1. Drug

    Olinciguat

    go.drugbank.com/drugs/DB15238
    Investigational

    Olinciguat is under investigation in clinical trial NCT03892499 (A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator

  2. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene. … Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757]

  3. Drug

    VY-HTT01

    go.drugbank.com/drugs/DB16999
    Investigational

    VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. … VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.

  4. Drug

    Sparfloxacin

    go.drugbank.com/drugs/DB01208
    ApprovedWithdrawn

    Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA top...

  5. Drug

    Human papillomavirus type 6 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10299
    ApprovedInvestigational

    The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.

  6. Drug

    Torcetrapib

    go.drugbank.com/drugs/DB06281
    Investigational

    of atorvastatin and the study drug. … Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination

  7. Drug

    Sparteine

    go.drugbank.com/drugs/DB06727
    ApprovedWithdrawn

    Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents.

  8. Drug

    Safflower oil

    go.drugbank.com/drugs/DB09446
    ApprovedInvestigationalWithdrawn

    acid [A32677, A32679], depending on the flower type. … Safflower (_Carthamus tinctorius_ L) is a herbaceous plant in the Asteraceae family.

  9. Drug

    Telapristone acetate

    go.drugbank.com/drugs/DB05253
    Investigational

    Telapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.

  10. Drug

    (Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide

    go.drugbank.com/drugs/DB06941
    Experimental

    This compound belongs to the phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. This drug targets the protein S100B.